Atlas of Genetics and Cytogenetics in Oncology and Haematology


Home   Genes   Leukemias   Solid Tumours   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

X Y 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 NA

Lung: Non-small cell carcinoma

Identity

ICD-Topo C340-C343,C348-C349
Phylum Lung, Heart, Skin, Other:Lung:Nonsmall cell carcinoma
Note See also the overview on lung tumors

Classification

    Non-small cell carcinomas are divided into three main categories according to the predominant morphology of the tumour cells as determined by light microscopy. Although it is possible to distinguish different histological sub-groups in this way, or by using gene expression profiling, treatment is currently decided on the basis of tumour staging, age and performance status and is independent of tumour histology. In the future, this may change as new drugs are developed and as more information is gathered on the predictive power of such expression profiles.

Clinics and Pathology

Pathology Squamous cell carcinoma:
Approximately 30% of lung tumours are classified as squamous cell carcinomas (SCC). Whilst this was the most common sub-type seen in the past, the incidence of SCC appears to be decreasing relative to adenocarcinoma, probably as a consequence of historical changes in the way that cigarettes are smoked (lower tar and filter tips promoting deeper inhalation). SCC cells are large, flattened and stratified with a high cytoplasm to nucleus ratio. Key diagnostic features include the presence of intracytoplasmic keratin which may be linked to the presence of intercellular bridges and squamous pearl formation. Most SCC arise centrally within the main, lobar, segmental or subsegmental bronchi but some occur more peripherally. The tumour mass generally extends into the lumen of the airway with invasion into the underlying wall.

Adenocarcinoma:
A further 30-50% of tumours are defined as adenocarcinomas (ADC). This tumour type is the most common in non-smokers and women and it is more frequently associated with pleural effusions and distant metastases. ADC may be further sub-classified into:

  • acinar (gland forming),
  • papillary,
  • bronchioalveolar (BAC),
  • solid with mucin and
  • mixed.
    As most ADC are histologically heterogeneous, they generally fall into the mixed category. The tumours usually arise in the smaller peripheral airways (as distinct from the cartilage bearing bronchi) but they can be found more centrally. The key diagnostic features of ADC include gland formation - where the tumour cells are arranged around a central lumen - and/or mucin production. ADC is the tumour type most commonly found associated with fibrotic scars, which are thought to be caused in some way by the tumour. BAC, which represents 2-6% of total lung cancer is distinct from other sub-types both in terms of its growth pattern, which is lepidic (typically arising beyond the terminal bronchioloes, where it spreads along the alveolar septa causing minimal structural damage) and by the fact that it is non-invasive.

    Large cell carcinoma:
    Approximately 10% of NSCLC are defined as large cell carcinomas (LCC). This is a diagnosis of exclusion. Where a poorly differentiated tumour has none of the defining features of SCLC, SCC or ADC it may be classified as LCC: that is, where the cells of the lesion are not-columnar in shape, do not contain mucous, do not show squamous differentiation, and do not have neuroendocrine properties or small cell characteristics. Tumours tend to consist of large cells with abundant cytoplasm, large nuclei and prominent nucleoli and they may occur peripherally or centrally. Variants of LCC include clear cell carcinoma, giant cell carcinoma and large cell neuroendocrine carcinoma (LCNEC).

    Pre-invasive lesions
    The bronchial epithelium of the larger airways is a pseudo-stratified epidermal layer. The most frequent cell types present are ciliated columnar cells, interspersed mucous-producing goblet cells and, lying closely against the basement membrane, multi-potent basal epithelial cells. The basal (or reserve) cell has a repair capacity in that it is able to differentiate, as required, into the other mature cells of the larger conducting airways. In the smaller terminal and respiratory bronchioles, basal cells are not present. The reserve cells of these epithelia are the cuboidal, non-ciliated Clara cells. It has been suggested that the multi-potent basal cell or a stem cell precursor of such cells may represent a common lung cancer progenitor.

    In chronic smokers, the cells of the tracheo-bronchial tree are repeatedly exposed to a range of carcinogenic compounds. Consequently, histologically-recognisable reactive and pre-neoplastic changes can generally be seen scattered throughout the airways of long-time smokers. In situ (pre-invasive) carcinoma (CIS: full thickness cytological atypia, increased nuclear to cytoplasmic ratio) is a recognised precursor of squamous cell carcinoma. This is the end of a spectrum of pre-neoplastic transformation that ranges from squamous metaplasia (change in appearance of cuboidal cells towards squamous morphology) through mild to severe dysplasia (loss of polarity, increasing disorder) to CIS. A second pre-neoplastic state is represented by Atypical Adenomatous Hyperplasia (AAH). This is a bronchioalveolar proliferation of slightly atypical cuboidal cells that falls short of the criteria for BAC: it is a recognised precursor to adenocarcinoma.

  • Cytogenetics

    Note Lung carcinomas represent the end-stage of the neoplastic transformation of a stem (or stem-cell like) cell that has been repeatedly exposed over many years to high levels of multiple carcinogens. It is therefore not surprising that the genetic and epigenetic lesions seen in lung cancer cells are complex. Correspondingly, frequent numerical and structural chromosomal alterations are reported in NSCLC. Whilst many changes are common, some perhaps occurring more often in one histological class over another, few if any have been shown to be exclusive to particular sub-types of disease or prognostic groupings. At the molecular level, highly complex patterns of allelic imbalance (LOH) have been observed in primary tumours. Again, few if any of these have been strongly related to diagnosis or prognosis. No balanced chromosomal translocations have yet been associated characteristically with NSCLC.
    Cytogenetics
    Morphological
    The generally low mitotic index of lung carcinomas makes karyotypic analysis difficult. However, common numerical changes observed include the losses of chromosomes 9 and 13 and trisomy for chromosome 7. Unbalanced rearrangements have been reported to occur frequently within chromosomes 1, 3, 5, 6, 7, 8, 9, 11, 13, 14, 15, 17 and 19 and it is thought that the loss of genetic material due to such events might encompass, to some lesser extent, all chromosome arms. Arms which frequently show clear loss include; 9p, 3p,6q, 8p, 9q, 13q, 17p, 18q, 19p, 21q, and 22q with those often associated with gains being 7p, 7q, 1q, 3q, 5p, 11q and 12q.
    Cytogenetics Molecular Comparative genomic hybridisation (CGH) has been used to extend conventional karyotypic analysis in NSCLC. Prominent imbalances seen in several studies include losses of 3p, 8p, 9p, 13q and 17p and gain of chromosome arms 1q, 3q, 5p and 8q. Regional amplification has been reported for 3q26, 8q24, 3q13, 3q28-qter, 7q11.2, 8p11-12, 12p12 and 19q13.1-13.2. Minimally localised under-represented regions include 3p14-21, 8p21-23 and 17p12-13. CGH analysis has also suggested that some alterations are more commonly seen in particular NSCLC sub-types with gain of 3q24-qter more common in SCC than ADC and gain of 1q22-32 more common in ADC than SCC.

    Genes involved and Proteins

    Note Consistent somatic mutation of coding sequence in primary tumours is strong evidence that a particular gene has been or is involved in the development of a neoplastic phenotype. In common with a range of tumours, particular genes are therefore clearly associated with NSCLC initiation or progression. These include TP53 (17p13.1), CDKN2A encoding p16 and p14 (9p21.3) and KRAS2 (12p12.1). Each of these genes lies within a region identified cytogenetically as implicated in NSCLC.

    The amplification of chromosomal regions containing genes implicated in cell growth has also been reported in primary NSCLC, albeit at a relatively low frequency. Such data are suggestive of the involvement of these sequences in neoplasia but they are weaker than direct mutational evidence given that the amplified regions generally contain a number of distinct genes, the relative contributions of each of which to the tumour phenotype is usually unknown. Genes reported as amplified in primary lesions include CCND1, encoding cyclin D1 (11q13.3), TP73L, encoding p63 (3q28), KRAS2 (12p12), MYC (8q24.21) and EGFR (7p11.2).

    A number of genes that are encoded from within chromosomal regions which show LOH or homozygous deletion in certain lesions have been identified. Such sequences may show a lack of expression in primary tumour cells compared to at least most of the cells in normal lung tissue. This lack of expression may in turn be correlated with hypermethylation of the relevant promoter sequence. Examples of such genes include RASSF1A (3p21) and CDKN2A (9p21.3). It is tempting to speculate that genes which show high levels of promoter methylation in tumour over normal tissue have been somatically inactivated by such methylation and are therefore likely to represent causally involved tumour suppressors. Whilst this may well be true in specific instances, especially where the gene in question is mutationally inactivated in a separate fraction of lesions (CDKN2), it may not be so generally, as the methylation level seen in the tumour may be completely appropriate for the cell type of origin of the particular lesion.

    Whilst the data suggesting the involvement of an individual gene in a tumour type might not be compelling, when pathways or control points are considered, the evidence often becomes much stronger. The best example of this is perhaps damage to the genetic system controlling progression through the G1 restriction point of the cell cycle, beyond which the cell is committed to divide. Proteins intimately involved in this key decision point, cyclin D1, p16, and pRB are frequent targets of NSCLC miss-regulation and may be involved at the earliest stages of pre-neoplastic development.

    Microarray analyses: Recent microarray analyses have shown that gene expression profiling can be used to sub-divide tumours into existing histological classes. Perhaps more importantly, analyses of adenocarcinoma series have demonstrated that sub-groups of stage 1 lesions with better or worse survival can be identified from their expression patterns. Such data suggest that tumour behaviour may be, at least to some point, fixed very early in the disease process. From a different perspective, many genes have been shown to be commonly differentially expressed (over-represented) in NSCLC compared to normal lung, to some extent at least, irrespective of general histology. Such genes are potential diagnostic targets. More importantly, the study of their function, normal expression patterns and mechanisms of expression control may shed considerable light on the biology of lung cancer and the characteristics of the cell type(s) of origin. Preliminary analyses of genomics and/or proteomics highlighted sequences (S100A2, SERPINB5 encoding maspin and TP73L, encoding p63) in lung tumours and pre-neoplastic lesions supports such hypotheses and raise the possibility that some measure of tumour gene expression may result from a failure to appropriately inactivate particular sequences involved in the self-renewal phenotype of stem-cell (like) progenitors. It is anticipated that in the future, further detailed molecular investigations of gene expression in disease and normal tissues will lead to new prognostic, predictive, diagnostic, therapeutic and preventative tools.


    Other genes implicated (Data extracted from papers in the Atlas)

    Genes ABCC10 ACTN4 ACVRL1 ADAM9 ADAMTS1 ALK ANLN ANP32A APAF1 AREG
    BCAR1 BIRC2 BMP4 BNIP3L BUB1 C12orf5 CARD8 CCNB1 CCR1 CD151
    CD74 CDA CDC42 CDH1 CDT1 CSE1L CTDSPL CTNND1 CXCL17 CXCL5
    CYR61 DAPK1 DDR1 DIABLO DKK3 DLC1 DLX4 DLX5 DMTF1
    DPP4 DUSP1 DUSP6 DVL1 E2F1 ECT2 EFEMP1 EGR1 EIF2AK2 EIF4B
    EML4 ENO1 ENOX2 ENPP2 EPHA2 EPHA3 EPHB6 ERBB2 ERBB3 ERRFI1
    EZH2 FAM107A FEN1 FOXQ1 FUBP1 GNB2L1 GPRC5A GRPR HELLS HGF
    HNRNPD HYAL2 ID1 IDO1 IGF2BP1 IL17A IL1RN IL22 IL7R IRS1
    JAK1 KIF14 KLK11 KLK4 KLK5 KLK8 LATS2 LPHN2 LRIG3
    MAGEA3 MAP3K7 MAPK1 MAPK3 MIR107 MIR126 MIR133B MIR143 MIR146B MIR200C
    MIR30A MIR221 MIR222 MKI67 MMP26 MYLK NAT1 NFATC2 NFKB1 NNMT
    NOTCH3 NUMB ORAI3 PIAS1 PIAS3 PLA2G4A PLAUR POU3F2 PPARG PRKAB1
    PRKCI PTGIS PTGS2 PTPRD PXN RAF1 RAPGEF1 RASSF2 RBL2 RCHY1
    REPS2 REST RND3 RPA2 RPL26 RRM1 RUVBL1 S100A2 S100P SEP15
    STIL SLIT2 SOX2 SPRY1 SRSF1 SSX2 STK11 TACC3 TEK TGFBR2
    TGFBR3 TGM2 THBS2 TMSB10 TOP1 TOPORS TPBG TRIO TWIST1 TXN
    USP1 USP7 VCP VIP VTCN1 WIF1 WNT1 WWOX WWTR1 YBX1
    YPEL5 ZBTB33 ZBTB7A

    Translocations implicated (Data extracted from papers in the Atlas)

    External links

    Mitelman database
    COSMICHisto = - Site = lung (COSMIC)
    arrayMapTopo ( C34) arrayMap (Zurich)
    Other databaseTumor Portal - Broad Institute

    Bibliography

    Pathology of the Lung: second edition.
    Thurlbeck WM and Churg AM Eds
    Thieme Medical Publishers, Inc..
     
    Advances in the analysis of chromosome alterations in human lung carcinomas.
    Testa JR, Liu Z, Feder M, Bell DW, Balsara B, Cheng JQ, Taguchi T
    Cancer genetics and cytogenetics. 1997 ; 95 (1) : 20-32.
    PMID 9140450
     
    Tumours and Tumour-like Lesions of the Lung.
    Carter D and Patchefsky AS
    WB Saunders Company (pubs). : page 1998.
     
    Lung Cancer: Principles and Practice.
    Pass HI, Mitchell JB, Johnson DH
    Lippincott Williams..
     
    Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses.
    Bhattacharjee A, Richards WG, Staunton J, Li C, Monti S, Vasa P, Ladd C, Beheshti J, Bueno R, Gillette M, Loda M, Weber G, Mark EJ, Lander ES, Wong W, Johnson BE, Golub TR, Sugarbaker DJ, Meyerson M
    Proceedings of the National Academy of Sciences of the United States of America. 2001 ; 98 (24) : 13790-13795.
    PMID 11707567
     
    Diversity of gene expression in adenocarcinoma of the lung.
    Garber ME, Troyanskaya OG, Schluens K, Petersen S, Thaesler Z, Pacyna-Gengelbach M, van de Rijn M, Rosen GD, Perou CM, Whyte RI, Altman RB, Brown PO, Botstein D, Petersen I
    Proceedings of the National Academy of Sciences of the United States of America. 2001 ; 98 (24) : 13784-13789.
    PMID 11707590
     
    Chromosomal imbalances in human lung cancer.
    Balsara BR, Testa JR
    Oncogene. 2002 ; 21 (45) : 6877-6883.
    PMID 12362270
     
    Gene-expression profiles predict survival of patients with lung adenocarcinoma.
    Beer DG, Kardia SL, Huang CC, Giordano TJ, Levin AM, Misek DE, Lin L, Chen G, Gharib TG, Thomas DG, Lizyness ML, Kuick R, Hayasaka S, Taylor JM, Iannettoni MD, Orringer MB, Hanash S
    Nature medicine. 2002 ; 8 (8) : 816-824.
    PMID 12118244
     
    Expression profiling of primary non-small cell lung cancer for target identification.
    Heighway J, Knapp T, Boyce L, Brennand S, Field JK, Betticher DC, Ratschiller D, Gugger M, Donovan M, Lasek A, Rickert P
    Oncogene. 2002 ; 21 (50) : 7749-7763.
    PMID 12400018
     
    Tumor suppressor genes on chromosome 3p involved in the pathogenesis of lung and other cancers.
    Zabarovsky ER, Lerman MI, Minna JD
    Oncogene. 2002 ; 21 (45) : 6915-6935.
    PMID 12362274
     
    Significance of p63 amplification and overexpression in lung cancer development and prognosis.
    Massion PP, Taflan PM, Jamshedur Rahman SM, Yildiz P, Shyr Y, Edgerton ME, Westfall MD, Roberts JR, Pietenpol JA, Carbone DP, Gonzalez AL
    Cancer research. 2003 ; 63 (21) : 7113-7121.
    PMID 14612504
     
    Cyclin D1 overexpression in bronchial epithelia of patients with lung cancer is associated with smoking and predicts survival.
    Ratschiller D, Heighway J, Gugger M, Kappeler A, Pirnia F, Schmid RA, Borner MM, Betticher DC
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2003 ; 21 (11) : 2085-2093.
    PMID 12775733
     
    Maspin - the most commonly-expressed gene of the 18q21.3 serpin cluster in lung cancer - is strongly expressed in preneoplastic bronchial lesions.
    Smith SL, Watson SG, Ratschiller D, Gugger M, Betticher DC, Heighway J
    Oncogene. 2003 ; 22 (54) : 8677-8687.
    PMID 14647462
     
    REVIEW articlesautomatic search in PubMed
    Last year articlesautomatic search in PubMed

    Contributor(s)

    Written02-2004Jim Heighway, Daniel C Betticher

    Citation

    This paper should be referenced as such :
    Heighway, J ; Betticher, DC
    Lung: Non-small cell carcinoma
    Atlas Genet Cytogenet Oncol Haematol. 2004;8(2):134-136.
    Free online version   Free pdf version   [Bibliographic record ]
    URL : http://AtlasGeneticsOncology.org/Tumors/LungNonSmallCellID5141.html

    © Atlas of Genetics and Cytogenetics in Oncology and Haematology
    indexed on : Tue Sep 23 17:33:54 CEST 2014


    Home   Genes   Leukemias   Solid Tumours   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

    For comments and suggestions or contributions, please contact us

    jlhuret@AtlasGeneticsOncology.org.